Following a recent late‐stage clinical trial failure of Incyte (an IDO1 inhibitor) in combination with pembrolizumab (an anti‐PD1 antibody) in patients with advanced malignant melanoma,57 researchers are exploring the multiple and complex roles of IDO1 in disease. The gene discussed is IDO1; the disease is melanoma.